Ding Liming, Wang Xingyu, Mao Tiantao, Li Jibin
School of Public Health, Chongqing Medical University, Chongqing 400016, China.
People's Hospital of Wuxi, Chongqing 405800, China.
Diagnostics (Basel). 2023 Jun 26;13(13):2179. doi: 10.3390/diagnostics13132179.
Sarcopenia is a key factor affecting the prognosis of cancer patients; however, identifying patients at risk remains challenging. The serum creatinine/cystatin C ratio (CCR) and the sarcopenia index (SI) are new biomarkers for sarcopenia screening. The Ishii test score is an equation based on age, grip strength, and calf circumference for sarcopenia screening. However, their performances in advanced cancer patients have not been thoroughly studied. We aimed to evaluate and compare the accuracy of three screening tools in diagnosing cancer-related sarcopenia.
A total of 215 cancer patients with a median age of 60.5 y were enrolled in this cross-sectional study. The Asian Working Group for Sarcopenia 2019 (AWGS2019) criteria were used as a standard. The diagnostic accuracies of the CCR, SI, and Ishii screening test were analyzed in terms of sensitivity, specificity, negative and positive predictive values, the Youden index, and the receiver operating characteristic (ROC) curve.
According to the AWGS2019 criteria, the prevalence of sarcopenia and severe sarcopenia was 47.9% and 18.6%, respectively. The CCR, SI (positively), and Ishii scores (negatively) were correlated with muscle mass. Accordingly, sarcopenia was negatively correlated with CCR and SI, while it was significantly positively correlated with the Ishii score. In males, the AUCs of the CCR, SI, and Ishii scores were 0.743 (95%CI 0.65-0.836), 0.758 (95%CI 0.665-0.852), and 0.833 (95%CI 0.751-0.909), respectively. In females, the AUCs of the CCR, SI, and Ishii scores were 0.714 (95%CI 0.61-0.818), 0.737 (95%CI 0.635-0.839), and 0.849 (95%CI 0.775-0.932), respectively. The AUC of the Ishii score was significantly higher than that of the other screening tools ( < 0.001). The cut-off value of the optimal Ishii score was 102.3 (sensitivity: 93.2%, specificity: 59.1%) for males and 98.3 (sensitivity: 93.3%, specificity: 64.7%) for females.
The CCR and SI based on serum CysC and creatinine had a remarkably similar overall diagnostic accuracy for sarcopenia in advanced cancer. Among the above three sarcopenia screening tools, the Ishii score chart seemed to have better predictive values of sarcopenia in cancer patients.
肌肉减少症是影响癌症患者预后的关键因素;然而,识别有风险的患者仍然具有挑战性。血清肌酐/胱抑素C比值(CCR)和肌肉减少症指数(SI)是用于肌肉减少症筛查的新生物标志物。石井测试评分是一个基于年龄、握力和小腿围度的用于肌肉减少症筛查的公式。然而,它们在晚期癌症患者中的表现尚未得到充分研究。我们旨在评估和比较三种筛查工具在诊断癌症相关肌肉减少症方面的准确性。
本横断面研究共纳入215例中位年龄为60.5岁的癌症患者。采用2019年亚洲肌肉减少症工作组(AWGS2019)标准作为参照标准。从敏感性、特异性、阴性和阳性预测值、约登指数以及受试者工作特征(ROC)曲线等方面分析CCR、SI和石井筛查测试的诊断准确性。
根据AWGS2019标准,肌肉减少症和严重肌肉减少症的患病率分别为47.9%和18.6%。CCR、SI(呈正相关)和石井评分(呈负相关)与肌肉量相关。因此,肌肉减少症与CCR和SI呈负相关,而与石井评分呈显著正相关。在男性中,CCR、SI和石井评分的曲线下面积(AUC)分别为0.743(95%CI 0.65 - 0.836)、0.758(95%CI 0.665 - 0.852)和0.833(95%CI 0.751 - 0.909)。在女性中,CCR、SI和石井评分的AUC分别为0.714(95%CI = 0.61 - 0.818)、0.737(95%CI 0.635 - 0.839)和0.849(95%CI 0.775 - 0.932)。石井评分的AUC显著高于其他筛查工具(<0.001)。男性最佳石井评分的截断值为102.3(敏感性:93.2%,特异性:59.1%),女性为98.3(敏感性:93.3%,特异性:64.7%)。
基于血清胱抑素C和肌酐的CCR和SI在晚期癌症肌肉减少症的总体诊断准确性上非常相似。在上述三种肌肉减少症筛查工具中,石井评分表在癌症患者肌肉减少症的预测价值方面似乎更好。